Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001884770 | SCV002157948 | uncertain significance | not provided | 2022-03-09 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LRP2 protein function. This variant has not been reported in the literature in individuals affected with LRP2-related conditions. This variant is present in population databases (rs376039022, gnomAD 0.01%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 3042 of the LRP2 protein (p.Gly3042Arg). |
Fulgent Genetics, |
RCV002490159 | SCV002803846 | uncertain significance | Donnai-Barrow syndrome | 2022-05-09 | criteria provided, single submitter | clinical testing |